lilly direct tirzepatide vial Eli Lowers Cost of Single-Dose Zepbound Vials Lilly launches vials of weight-loss

For a 220-pound person, that translates to roughly 35 to 50 pounds

, , , ,

10.1210/en.2012-1937

Highlights Understanding weight as a whole health ecosystem, not a willpower issue Ashleys journey and how generational experiences shape weight health The main weight-health hormones and how they influence the body GLP-1 medications: who they help, who they may harm, and what practitioners must screen for Understanding these medications system-wide effects as a practitioner Microdosing vs low-dose GLP-1 and why individualized dosing is critical A multifactorial framework for assessing weight-health hormone function Supporting long COVID, MCAS, endometriosis, autoimmune issues, and chronic pain How GLP-1 agonists may influence gut, immune, and receptor-level functioning Peptides, protein diversity, and their impact on pain and metabolic health Differences between short-acting and long-acting GLP-1 medications How to approach weaning off GLP-1s Examining internalized bias, ableism, and beauty standards in weight-related decisions Connect with Ashley Koff, RD The Better Nutrition Program GLP-1 Assessment Ashley Koffs Book | Your Best Shot: The Personalized System for Optimal Weight HealthGLP-1 Shot or Not Ashley Koff on Instagram @ashleykoffapproved About Ashley Koff, RD Ashley Koff, RD, is the founder of The Better Nutrition Program (BNP), the Nutrition Course Director for UC Irvines Susan Samueli Integrative Health Institutes Integrative and Functional Medicine Fellowship, and a faculty member at the Integrative and Functional Nutrition Academy (IFNA), where she teaches An Integrative and Functional Nutrition Approach to Obesity and Weight Management. She is also the author of the upcoming book, Your Best Shot (Harper One, January 6, 2026)

Certain content on this website, including text and images, may be generated or enhanced using artificial intelligence